C-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells

Oncogene

Volumn 29, Issue 7, 2010, Pages 978-991

  Madeo, A ^a   Vinciguerra, M ^b   Lappano, R ^a   Galgani, M ^b   Gasperi Campani, A ^c   Maggiolini, M ^a   Musti, A M ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

4 hydroxytamoxifen; AP 1; Apoptosis; C Fos; C Jun; JNK

Indexed keywords

4 HYDROXYTAMOXIFEN; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA FRAGMENTATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION;

ANIMALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; ORGAN SPECIFICITY; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ESTROGEN; SUBSTRATE SPECIFICITY; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 77149152500     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.400     Document Type: Article

References (49)

1. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A et al. (2007). G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67: 1859-1866.
2. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A et al. (2008). Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149: 3799-3808.
3. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390: 191-214.
4. Bannister AJ, Oehler T, Wilhelm D, Angel P, Kouzarides T. (1995). Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene 11: 2509-2514. (Pubitemid 26023818)
5. Basu S, Ma R, Boyle PJ, Mikulla B, Bradley M, Smith B et al. (2004). Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis-platin, tamoxifen, melphalan, betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside. Glycoconj J 20: 563-577.
6. Behrens A, Sibilia M, Wagner EF (1999). Amino-terminal phosphor-ylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 21: 326-329.
7. Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
8. Dunn C, Wiltshire C, MacLaren A, Gillespie DA. (2002). Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal 14: 585-593.
9. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
10. Friesen C, Kiess Y, Debatin KM. (2004). A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 11(Suppl 1): S73-S85.
11. Ham J, Towers E, Gilley J, Terzano S, Randall R. (2005). BH3-only proteins: key regulators of neuronal apoptosis. Cell Death Differ 12: 1015-1020.
12. Hess J, Angel P, Schorpp-Kistner M. (2004). AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
13. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. (2005). Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10: 1395-1410.
14. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F et al. (2008). Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 27: 1472-1477.
15. Lee YS, Kang YS, Lee SH, Kim JA. (2000). Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 7: 925-932.
16. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B et al. (2000). TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol 164: 4277-4285.
17. Love RR. (1989). Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 7: 803-815.
18. Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E et al. (2004). Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 145: 1302-1313.
19. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V et al. (2004). The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279: 27008-27016.
20. Mandlekar S, Kong AN. (2001). Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477.
21. Mandlekar S, Yu R, Tan TH, Kong AN. (2000). Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000.
22. Morton S, Davis RJ, McLaren A, Cohen P. (2003). A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. Embo J 22: 3876-3886.
23. Musti AM, Treier M, Bohmann D. (1997). Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275: 400-402.
24. Nateri AS, Spencer-Dene B, Behrens A. (2005). Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285.
25. Nephew KP, Polek TC, Akcali KC, Khan SA. (1993). The antiestro-gen tamoxifen induces c-fos and jun-B, but not c-jun or jun-D, protooncogenes in the rat uterus. Endocrinology 133: 419-422.
26. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. (1997). A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 272: 18586-18594.
27. Papavassiliou AG, Treier M, Bohmann D. (1995). Intramolecular signal transduction in c-Jun. Embo J 14: 2014-2019.
28. Papavassiliou AG, Treier M, Chavrier C, Bohmann D. (1992). Targeted degradation of c-Fos, but not v-Fos, by a phosphoryla-tion-dependent signal on c-Jun. Science 258: 1941-1944.
29. Pope R, Mungre S, Liu H, Thimmapaya B. (2000). Regulation of TNF-alpha expression in normal macrophages: the role of C/EBPbeta. Cytokine 12: 1171-1181.
30. Porter AG, Janicke RU. (1999). Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104.
31. Price MA, Rogers AE, Treisman R. (1995). Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). Embo J 14: 2589-2601.
32. Prossnitz ER, Maggiolini M. (2009). Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308: 32-38.
33. Raivich G. (2008). c-Jun expression, activation and function in neural cell death, inflammation and repair. J Neurochem 107: 898-906.
34. Raivich G, Behrens A. (2006). Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog Neurobiol 78: 347-363.
35. Recktenwald CV, Kellner R, Lichtenfels R, Seliger B. (2008). Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res 68: 10086-10093.
36. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG et al. (2000). Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92: 1926-1934.
37. Shaulian E, Karin M. (2001). AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400.
38. Shen HM, Shi CY, Shen Y, Ong CN. (1996). Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1. Free Radic Biol Med 21: 139-146.
39. Smith CL, Nawaz Z, O'Malley BW. (1997). Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657-666.
40. Strober W. (2001). Trypan blue exclusion test of cell viability. Curr Protoc Immunol; Appendix 3: A.3B.1-2, Supplement 21.
41. Treisman R. (1995). Journey to the surface of the cell: Fos regulation and the SRE. Embo J 14: 4905-4913.
42. Vinciguerra M, Esposito I, Salzano S, Madeo A, Nagel G, Maggiolini M et al. (2008). Negative charged threonine 95 of c-Jun is essential for c-Jun N-terminal kinase-dependent phosphorylation of threonine 91/93 and stress-induced c-Jun biological activity. Int J Biochem Cell Biol 40: 307-316.
43. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A et al. (2006a). 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70: 1414-1423.
44. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S et al. (2006b). The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20: 631-646.
45. Wada T, Joza N, Cheng HY, Sasaki T, Kozieradzki I, Bachmaier K et al. (2004). MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol 6: 215-226.
46. Watson A, Eilers A, Lallemand D, Kyriakis J, Rubin LL, Ham J. (1998). Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J Neurosci 18: 751-762.
47. Weiss C, Schneider S, Wagner EF, Zhang X, Seto E, Bohmann D. (2003). JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. Embo J 22: 3686-3695.
48. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. (2001). Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29: 629-643.
49. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. (2004). Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 64: 4577-4584.